Andaris Quantison U.S. Phase II trial for myocardial perfusion imaging IND filed.
Executive Summary
ANDARIS QUANTISON U.S. PHASE II TRIAL TO ASSESS MYOCARDIAL PERFUSION as well as left ventricular opacification, the Nottingham, U.K.-based biotech company said. Andaris announced July 31 that it has filed an IND for its ultrasound contrast agent Quantison, a three-micron air-filled albumin microcapsule. The Phase II trial will begin as soon as possible following FDA clearance, the company said.